Icotrokinra Shows Superiority to Deucravacitinib in First Reported Head-to-head Trials Reinforcing Promise of Novel Targeted Oral Peptide for Treatment of Plaque Psoriasis
SPRING HOUSE, Pa. – Johnson & Johnson announced new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies which assessed the superiority of icotrokinra, a first-in-class investigational targeted oral peptide… Read More




